York, U.K.-based Abingdon Health Ltd. has signed a non-exclusive sales and distribution agreement in the U.K. and Europe for the AbC-19 rapid neutralizing antibody test with Naezing, U.K.-based Biosure UK. Abingdon Health is a member of the UK-Rapid Test Consortium. The companies plan to establish a strategic distribution relationship to enable them to identify and maximize opportunities for the sale of the AbC-19 rapid neutralizing antibody test in the U.K. and European territories.
San Diego-based Agena Bioscience Inc. signed an exclusive distribution agreement with Dubai, United Arab Emirates-based Alliance Global to bring the Massarray technology to many emerging markets across the Middle East, Africa, and Central Asia.
Santa Clara, Calif.-based Agilent Technologies Inc. reported the launch of a real-time reverse transcription (qRT) PCR-based diagnostic kit for the detection of SARS-CoV-2 RNA. The CE-IVD mark is in accordance with the European Union In Vitro Diagnostic Directive 98/79/EC and is available for immediate distribution.
Munich, Germany-based Brainlab AG reported the acquisition of Mint Medical GmbH, a Heidelberg, Germany-based company that develops image reading and reporting software for clinical routine and research. Together, Brainlab and Mint technologies will offer existing Mint customers the ability to link data across multiple oncological subspecialties, from clinical oncology to surgical oncology and radiotherapy. Integrating patient-reported outcomes measures (PROMs) from Visiontree, a Brainlab company, will further add longitudinal data to the pool available for analysis. Financial details of the deal were not disclosed.
Waltham, Mass.-based Corrona LLC, a provider of real-world evidence solutions, has changed its name to Corevitas to reflect its expanded strategic direction.
Embody Inc., of Norfolk, Va., reported the expansion and clinical use cases of its Tapestry biointegrative implant in the U.S. The product is the first collagen-based implant with a bioengineered micro-architecture and biostimulative, highly organized type I collagen chemistry specifically designed for the management and protection of tendon injuries. The technology has potential cross a broad range of tendon applications, including foot and ankle, knee and shoulder procedures.
Emitbio Inc., of Durham, N.C., reported new evidence demonstrating its light technology can inactivate variants of SARS-CoV-2. In a controlled laboratory environment, precise wavelengths of light achieved >99.9% reduction in viral load of the U.K. variant of SARS-CoV-2 (B.1.1.7) and the South Africa variant (B.1.351) at doses of energy that have previously proven safe to human tissue. The company has previously demonstrated the ability to inactivate coronaviruses with wide genetic variation (from SARS-CoV-2 to MERS-CoV), providing a basis for the belief that its proprietary light technology would kill SARS-CoV-2 variants. These findings confirm that belief, the company said.
Framingham, Mass.-based Empowerdx Inc., a Eurofins subsidiary, has released its direct-to-consumer U.S. FDA emergency use authorized COVID-19 Home Collection Kit on Amazon. The kits are available to consumers and businesses for $99 without a prescription, enabling greater access to COVID-19 testing.
Flowmetric Life Sciences Inc., of Doylestown, Pa., has launched a fleet of mobile COVID-19 testing labs capable of testing up to 300 individuals per day at any time and at any location.
Tokyo-based Konica Minolta Precision Medicine Inc. (KMPM) reported a five-year collaboration with Amazon Web Services Inc. (AWS), of Seattle. As the preferred cloud provider for KMPM, AWS will support the global build-out of the company’s Lattice initiate, an integrated diagnostic platform that combines genomics, pathology and radiology data along with other critical information to uncover new, clinically relevant biomarkers and create next-generation diagnostic tests. As part of the collaboration, Amazon made a financial investment in KMPM.
New York-based conversational artificial intelligence (AI) company Liveperson Inc., in partnership with Innova Medical Group Inc., of Pasadena, Calif., reported the launch of Bella Health with Innova, a novel COVID-19 rapid testing experience with AI-guided instructions to ensure accuracy. The new experience is being evaluated in a large-scale at-home rapid testing study led by Michael Mina, an assistant professor of epidemiology at Harvard T.H. Chan School of Public Health.
Mississauga, Ontario-based Medx Health Corp. and Empower Clinics Inc., of Vancouver, British Columbia, are partnering to pilot Medx’s Dermsecure Screening Platform at two Empower Clinics in Ontario, with plans for a broader market rollout pending the pilot’s completion.
Mro Corp., of Norristown, Pa., has acquired Northbrook, Ill.-based Cobius Healthcare Solutions LLC, a provider of reimbursement and compliance risk management tools for health care systems and physicians. The acquisition expands Mro’s software and workflow solutions in audit and denial management and compliance. Financial terms of the deal were not disclosed.
Nano-X Imaging Ltd., of Neve Ilan, Israel, said it is scaling up its semiconductor fabrication plant in South Korea in response to increased demand for its Nanox.Arc systems.
Mountain View, Calif.-based Nowrx Inc., a technology-enabled pharmacy, has launched Nowrx Telehealth, enabling patients to interact with physicians through a mobile app and receive prescribed medications on the same day or same hour. The first phase of Nowrx Telehealth includes the introduction of NowPrEP, a specialty service that includes a free physician assessment, lab testing and home delivery of pre-exposure prophylaxis (PrEP), a critical HIV prevention medication.
Onduo LLC, a Boston-based virtual and digital chronic care management service, has achieved full URAC Accreditation in Medicine for its consumer to provider (C2P) virtual telemedicine platform.
Revbio Inc., of Lowell, Mass., said it has been awarded the opportunity to conduct an in vivo research experiment on the International Space Station U.S. National Laboratory. This experiment will examine the osteoconductivity of its biomaterial when used in a microgravity environment.
Amsterdam-based Royal Philips NV and Opendoctor, of New York, have teamed up to deliver an integrated radiology patient engagement platform that leverages Opendoctor’s real-time online appointment scheduling services as part of Philips’ newly launched Patient Management Solution.
Seqonce Biosciences Inc., of Pasadena, launched its Azureseq One-Step Universal SARS-CoV-2 RT-qPCR E484K kit to detect a mutation found in SARS-CoV-2 variants B.135.1 (South Africa) and P.1 (Brazil). The research use only assay uses a single-tube reaction targeting the N1 nucleocapsid gene, both alleles of S gene E484K (G23012A), and includes RNaseP as a control. The company said it is a faster method of detecting variants of concern than sequencing.
Spectrum Health, a not-for-profit, integrated health system based in Grand Rapids, Mich., reported a partnership with Tytocare Ltd., a New York-based provider of an all-in-one modular device and examination platform. The integration of Tytocare into Spectrum Health’s current virtual care offerings enhances the health system’s ability to diagnose and treat patients remotely with in-depth, physical examinations during video visits.
Sterigenics SAS, a Rantigny, France-based subsidiary of Sotera Health, reported the expansion of its ethylene oxide facility in France to increase European sterilization capacity.
Thermo Fisher Scientific Inc., of Waltham, Mass., launched its Applied Biosystems Taqman SARS-CoV-2 Mutation Panel, a customizable menu of 22 verified real-time PCR assays for identification of SARS-CoV-2 mutations. The panel, for research use only, is designed to enable surveillance of variants that are causing COVID-19 infections in specific regions globally and allow laboratories to choose which mutations to track.
Uromedica Inc., of Plymouth, Minn., reported the initiation of its U.S. FDA investigational device exemption trial for Adjustable Continence Therapy (ACT) for treatment of female stress urinary incontinence. The trial will evaluate ACT’s safety and efficacy by enrolling up to 167 subjects with 12-months of follow-up.